Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure
- 27 March 2014
- journal article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 39 (4), 432-438
- https://doi.org/10.1111/jcpt.12154
Abstract
Carvedilol is the standard of care for heart failure (HF) patients. Carvedilol is partially metabolized by the highly polymorphic enzyme, CYP2D6. To reach an effective dose while avoiding adverse drug reactions (ADRs), testing of CYP2D6 genotype prior to carvedilol initiation may be considered. The objectives of this study were to determine CYP2D6 metabolic genotypes in an Israeli cohort of HF patients and to investigate the relationship between genotype, carvedilol dose and number of ADRs to determine the importance of CYP2D6 genotyping prior to treatment initiation. Ninety-three patients with HF on carvedilol were CYP2D6 genotyped and classified as poor (PM), intermediate (IM), extensive (EM) or ultrarapid (UM) metabolizers. Carvedilol dose and ADRs were calculated and correlated with genotype using linear regression statistic analysis. The distribution of the CYP2D6 phenotype in the Israeli population with HF is similar to the European general population. There were no significant differences of carvedilol dose and number of ADRs among genotype groups. Genotype group affiliation and number of adverse drug reactions were not predictive of carvedilol dose changes. Genotype group affiliation and number of adverse drug reactions were not predictive of carvedilol dose during therapy for patients with HF. The Israeli CYP2D6 phenotype distribution in HF patients was consistent with the frequency in the general European population.Keywords
Funding Information
- Din Diagnostic Ltd.
This publication has 31 references indexed in Scilit:
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing eventsPharmacogenetics and Genomics, 2006
- Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19Psychosomatics, 2006
- Impact of a Standardized Titration Protocol with Carvedilol in Heart Failure: Safety, Tolerability, and Efficacy—A Report from the GESICA RegistryCardiovascular Drugs and Therapy, 2005
- Genetic polymorphism of CYP2D6 in patients with cardiovascular disease - a cohort studyJournal of Clinical Pharmacy & Therapeutics, 2004
- The global epidemiology of heart failureMedical Clinics of North America, 2004
- INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOLDrug Metabolism and Disposition, 2004
- Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart FailureCirculation, 2002
- Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactionsBritish Journal of Clinical Pharmacology, 2000
- Clinical Pharmacology of CarvedilolJournal of Cardiovascular Pharmacology and Therapeutics, 1999